NYSE:TPB
NYSE:TPBTobacco

Has Turning Point Brands Rallies in 2025 Already Priced In Future Growth?

If you are wondering whether Turning Point Brands is still a smart buy after its big run up, you are not alone. This article is going to unpack exactly what the current price might be baking in. The stock has climbed 6.0% over the last week, 4.1% over the last month, and is now up an eye catching 72.5% year to date, with a massive 430.9% gain over three years and 151.2% over five years that has clearly changed how the market views its prospects. Recent attention around Turning Point Brands...
NasdaqGS:PLPC
NasdaqGS:PLPCElectrical

Preformed Line Products (PLPC): Assessing Valuation After First Dividend Increase Since 2001 Listing

Preformed Line Products (PLPC) just gave income focused investors something new to consider, approving a 5% hike to its quarterly dividend, the first increase since the company listed in 2001. See our latest analysis for Preformed Line Products. The move lands after a strong run, with the latest share price at $231.5 and an impressive year to date share price return of about 80%. The five year total shareholder return of roughly 267% shows that long term momentum has been firmly building. If...
NasdaqGS:NWL
NasdaqGS:NWLConsumer Durables

Newell Brands (NWL) Valuation After Job Cuts, Store Closures and Lowered Q4 Outlook

Newell Brands (NWL) just paired a sweeping productivity overhaul, including more than 900 job cuts and 20 Yankee Candle store closures, with lowered Q4 guidance as Latin America sales improve more slowly than management expected. See our latest analysis for Newell Brands. Despite the sweeping restructuring moves, the share price has shown a 1 month share price return of about 18% and a 7 day share price return near 5%. However, that bounce sits against a much steeper year to date share price...
NasdaqGS:NAVN
NasdaqGS:NAVNHospitality

Navan (NAVN) Valuation Check After 19% Monthly Slide and 30% Year-to-Date Share Price Drop

Navan (NAVN) has been under pressure lately, with the stock sliding about 19% over the past month and roughly 30% year to date. This has raised fresh questions about how investors should value its AI-driven travel platform. See our latest analysis for Navan. Zooming out, that sharp recent slide in Navan’s share price sits on top of an already weak year to date share price return. This suggests momentum has clearly cooled as investors reassess both growth runway and execution risk. If Navan’s...
NYSE:GFF
NYSE:GFFBuilding

Griffon (GFF): Revisiting Valuation After Strong Recent Share Price Momentum

Griffon (GFF) has quietly outperformed the broader market over the past week and month, and that steady climb is starting to draw attention from investors looking for durable industrial exposure. See our latest analysis for Griffon. The recent 1 month share price return of 7.88 percent, on top of a robust 3 year total shareholder return of 144.18 percent, suggests momentum is still firmly on Griffon’s side as investors reassess its growth and cash generation story. If Griffon’s run has you...
NasdaqGS:ALNY
NasdaqGS:ALNYBiotechs

Is It Too Late to Consider Alnylam Pharmaceuticals After Its Huge 2025 Share Price Surge?

Wondering if Alnylam Pharmaceuticals at around $412 a share is still a smart buy after its huge run, or if the upside has already been priced in. The stock is down 11.3% over the last week and 8.7% over the past month, but even after that pullback it is still up 76.6% year to date and 68.2% over the last 12 months. Those moves have come as investors refocus on Alnylam's RNAi drug pipeline, major partnerships with big pharma, and the growing commercial traction of its approved therapies. The...
NYSE:ABT
NYSE:ABTMedical Equipment

Assessing Abbott (ABT) Valuation After New Lingo CGM Expansion and Protein-Glucose Data Release

Abbott Laboratories (ABT) just widened the audience for its Lingo glucose sensor by rolling it out on Android, pairing that step with fresh real world data on how protein intake shapes daily glucose control. See our latest analysis for Abbott Laboratories. Those Lingo updates and new Ensure protein launches land while Abbott’s 1 year total shareholder return of about 10 percent edges ahead of its year to date share price return near 9 percent, suggesting steady long term momentum despite...
NYSE:A
NYSE:ALife Sciences

Assessing Agilent Technologies (A) Valuation After Recent Pullback in an Ongoing Longer-Term Uptrend

Agilent Technologies (A) slipped slightly in the latest session, extending its pullback over the past month even though its longer term performance remains positive. Investors are now weighing recent weakness against improving growth fundamentals. See our latest analysis for Agilent Technologies. With the share price around $142.87, Agilent’s recent 7 day and 30 day share price declines contrast with a solid 90 day share price return. This suggests momentum has cooled but has not reversed the...
NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

Is It Too Late To Consider Expedia After Its 214% Three Year Surge?

If you have been wondering whether Expedia Group is still a bargain after its huge run, you are not alone. This is exactly the moment when valuation matters most. The stock has climbed 8.8% over the last week, 6.0% over the past month and is now up 51.7% year to date, with a 53.6% gain over the last year and a 214.2% increase over three years. Some of this momentum has been fueled by ongoing strength in travel demand and Expedia's continued push into its B2B partnerships and loyalty...
NasdaqGS:AMD
NasdaqGS:AMDSemiconductor

3 Stocks Estimated To Be Trading Below Intrinsic Value By At Least 41.3%

As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, major indices like the S&P 500 and Dow Jones Industrial Average are nearing record highs, reflecting investor optimism. In this buoyant environment, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for investors seeking value in a market driven by monetary policy shifts.
NasdaqGS:KRYS
NasdaqGS:KRYSBiotechs

Krystal Biotech And 2 Other Growth Stocks Insiders Are Betting On

As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are closely watching growth companies with high insider ownership. In this environment, stocks like Krystal Biotech and others where insiders have significant stakes can be particularly attractive, as they often signal confidence in the company's potential amidst evolving economic conditions.
NasdaqCM:AIRJ
NasdaqCM:AIRJMachinery

Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks

As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are keenly observing potential opportunities across various sectors. While large-cap stocks often dominate headlines, penny stocks—typically smaller or newer companies—continue to pique interest due to their potential for significant returns when backed by solid financials. Despite being considered a relic of past trading days, penny stocks still offer intriguing prospects...
NYSEAM:IDR
NYSEAM:IDRMetals and Mining

US Market's Undiscovered Gems Featuring Three Promising Small Caps

As the U.S. market experiences a surge following the Federal Reserve's decision to cut interest rates, small-cap stocks have been catching investors' attention, with the Russell 2000 reaching new all-time highs. In this dynamic environment, identifying promising small-cap companies involves looking for those that demonstrate resilience and potential growth despite broader economic uncertainties.
NasdaqGS:HST
NasdaqGS:HSTHotel and Resort REITs

Dividend Stocks To Consider In December 2025

As the U.S. stock market experiences a surge following the Federal Reserve's decision to cut interest rates, investors are eyeing opportunities in dividend stocks that can offer steady income amidst fluctuating market conditions. A good dividend stock typically combines strong fundamentals with a reliable payout history, making it an attractive option for those looking to balance growth potential with income stability in today's dynamic economic landscape.